[Federal Register Volume 81, Number 56 (Wednesday, March 23, 2016)]
[Notices]
[Page 15565]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-06534]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Manufacturer of Controlled Substances Registration: Cody 
Laboratories, Inc.

ACTION: Notice of registration.

-----------------------------------------------------------------------

SUMMARY: Cody Laboratories, Inc. applied to be registered as a 
manufacturer of a certain basic class of controlled substance. The Drug 
Enforcement Administration (DEA) grants Cody Laboratories, Inc. 
registration as a manufacturer of this controlled substance.

SUPPLEMENTARY INFORMATION: By notice dated October 13, 2015, and 
published in the Federal Register on October 21, 2015, 80 FR 63835, 
Cody Laboratories, Inc., Steven Hartman--Vice President of Compliance, 
601 Yellowstone Avenue, Cody, Wyoming 82414 applied to be registered as 
a manufacturer of certain basic classes of controlled substances. No 
comments or objections were submitted for this notice.
    The DEA has considered the factors in 21 U.S.C. 823(a) and 
determined that the registration of Cody Laboratories, Inc. to 
manufacture the basic classes of controlled substances is consistent 
with the public interest and with United States obligations under 
international treaties, conventions, or protocols in effect on May 1, 
1971. The DEA investigated the company's maintenance of effective 
controls against diversion by inspecting and testing the company's 
physical security systems, verifying the company's compliance with 
state and local laws, and reviewing the company's background and 
history.
    Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 
CFR 1301.33, the above-named company is granted registration as a bulk 
manufacturer of methadone intermediate (9254), a basic class of 
controlled substance listed in schedule II.
    The company plans to manufacture the listed controlled substance as 
an intermediate in the manufacture of an active pharmaceutical 
ingredient to sell to its customers.

    Dated: March 14, 2016.
Louis J. Milione,
Deputy Assistant Administrator.
[FR Doc. 2016-06534 Filed 3-22-16; 8:45 am]
 BILLING CODE 4410-09-P